ERGOT Faculty Macey Henderson, JD PhD has been nominated for UNOS Board of Directors 2017!
A kidney donor herself, Dr. Henderson applies her background in law, ethics, health policy and management to support her research into health outcomes of live kidney donors and transplant patients.
OPTN/UNOS member voting representatives will receive a ballot and biographical information for the nominees in early 2017.
You can follow Macey on twitter @MaceyLHenderson.
Dr. Allan Massie’s A Risk Index for Living Donor Kidney Transplantation was listed as one of the Top 10 Most Accessed Articles of 2016.
Choosing between multiple living kidney donors, or evaluating offers in kidney paired donation, can be challenging because no metric currently exists for living donor quality. Furthermore, some deceased donor (DD) kidneys can result in better outcomes than some living donor kidneys, yet there is no way to compare them on the same scale. To better inform clinical decision-making, we created a living kidney donor profile index (LKDPI) on the same scale as the DD KDPI, using Cox regression and adjusting for recipient characteristics.
The article was published in the July issue of The American Journal of Transplantation.
Completing the trilogy of papers published in the December issue of the American Journal of Transplantation that was dedicated to living donors, our lab looks for Patterns of End-Stage Renal Disease Caused by Diabetes, Hypertension, and Glomerulonephritis in Live Kidney Donors.
We looked at studies averaging less than 10 years of follow-up to better understand postdonation ESRD.
Following the American Journal of Transplantation’s theme of giving for their December article, they published our paper featuring our Smartphone App for Increasing Live Organ Donation.
The idea came from talking to waitlisted candidates for kidney transplant who reported substantial barriers to identifying a live donor. Our app aims to help ESRD patients eligible for transplantation create a dialog that tells their story and helps them reach out to friends and family through social medias.
That app, as of this blog post, is still in development.
The American Journal of Transplantation dedicated their December issue to organ donors who gave the gift of life to over 13,066 people this year (as of 11/18/2016).
At ERGOT, we care about the health and well being of live donors. In Recipient Outcomes Following Transplantation of Allografts From Live Kidney Donors Who Subsequently Developed End-Stage Renal Disease, data shows that preexisting kidney disease might be one mechanism underlying live donor end-stage renal disease.
The Fall 2016 issue of Hopkins Medicine calls him the “Transplant Titan.” We just call him Dorry, and he’s leading a dynamic and life-saving campaign to make organs available to those who need them.
ERGOT’s Douglas Mogul, MD MPH led a team to create the new Facebook application: Liver Space. Mogul wanted to create a community that connected pediatric liver disease patients and their families and provided them with useful information.
“It’s designed to strengthen online communities, serving as a bridge to health care providers and a portal for conducting research,” Mogul told Sarah Richards at Johns Hopkins.
Mogul is currently in talks about creating a similar site for patients with kidney disease.
Join us as ERGOT founder and director Dorry Segev, MD PhD leads a discussion with student speakers Ashton Shaffer, Jessica Ruck, and Alyssa Martin about the first HIV-Positive to HIV-Positive in the United States.
The talk will take place at 4:30pm on Monday, November 21 in Miller Research Building on the ground floor.
Drs. Niraj Desai and Christine Durand talk with CBS Baltimore about transplanting patients with hepatitis C-infected kidneys. The Johns Hopkins trial includes 10 patients from Baltimore, 5 of which have already been transplanted.
This is now a viable option now the hepatitis C is curable. This has the potential to shrink the transplant waitlist which is currently over 200,000 people in the US, 82-percent of whom need kidneys.
“If we had enough organs, we wouldn’t do this,” says Dr. Desai.
